Hormone replacement therapy
暂无分享,去创建一个
[1] M. Pike,et al. Estrogen-progestin replacement therapy and endometrial cancer. , 1998, Journal of the National Cancer Institute.
[2] Research on the menopause in the 1990s. Report of a WHO Scientific Group. , 1996, World Health Organization technical report series.
[3] G. Penney,et al. A population based survey of women's experience of the menopause , 1996, British journal of obstetrics and gynaecology.
[4] E. Barrett-Connor,et al. Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study. , 1997, JAMA.
[5] Svend Kreiner,et al. Hormone replacement therapy and risk of non-fatal stroke , 1997, The Lancet.
[6] S. Cummings,et al. Hormone therapy to prevent disease and prolong life in postmenopausal women , 1992, Annals of internal medicine.
[7] Ján,et al. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. , 1995, JAMA.
[8] A. LaCroix,et al. Estrogen replacement therapy and prognosis after first myocardial infarction. , 1997, American journal of epidemiology.
[9] J A Kanis,et al. Estrogens, the menopause, and osteoporosis. , 1996, Bone.
[10] H. Genant,et al. Low-Dose Esterified Estrogen Therapy: Effects on Bone, Plasma Estradiol Concentrations, Endometrium, and Lipid Levels , 1997 .
[11] A. Miller,et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. , 1995, Journal of the National Cancer Institute.
[12] D. Torgerson,et al. Randomized trial of osteoporosis screening. Use of hormone replacement therapy and quality-of-life results. , 1997, Archives of internal medicine.
[13] S B Hulley,et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. , 1998, Controlled clinical trials.
[14] C. Joyce,et al. Quality of life after the menopause: influence of hormonal replacement therapy. , 1994, American journal of obstetrics and gynecology.
[15] Julian Peto,et al. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.
[16] B. Rosner,et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. , 1992, The New England journal of medicine.
[17] H. Newnham,et al. Coronary heart disease. Women's hearts are hard to break. , 1997, Lancet.
[18] S. Sidney,et al. Increased risk of cholecystectomy in users of supplemental estrogen. , 1988, Gastroenterology.
[19] Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. , 1996, JAMA.
[20] A. Lane,et al. Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen , 1992, Annals of Internal Medicine.
[21] L. Kuller,et al. Estrogen replacement therapy and mortality among older women. The study of osteoporotic fractures. , 1997, Archives of internal medicine.
[22] H. Genant,et al. LOW-DOSE ESTERIFIED ESTROGEN THERAPY : EFFECTS ON BONE, PLASMA ESTRADIOL CONCENTRATIONS, ENDOMETRIUM, AND LIPID LEVELS , 1998 .
[23] R. Califf,et al. Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. , 1996, Journal of the American College of Cardiology.
[24] C. Furberg,et al. Venous thromboembolic events associated with hormone replacement therapy. , 1997, JAMA.
[25] H. Genant,et al. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. , 1996, JAMA.
[26] H. Newnham,et al. Women's hearts are hard to break , 1997, The Lancet.
[27] R. Lindsay,et al. Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis. , 1998, The American journal of clinical nutrition.
[28] D. McClish,et al. Estrogen Therapy in the Management of Urinary Incontinence in Postmenopausal Women: A Meta-Analysis. First Report of the Hormones and Urogenital Therapy Committee , 1994, Obstetrics and gynecology.
[29] H. Tunstall-Pedoe. Myth and paradox of coronary risk and the menopause , 1998, The Lancet.
[30] P. Newcomb,et al. Postmenopausal hormone use and risk of large-bowel cancer. , 1995, Journal of the National Cancer Institute.
[31] E. Barrett-Connor,et al. Hormone replacement therapy, heart disease, and other considerations. , 1998, Annual review of public health.
[32] K. Yaffe,et al. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. , 1998, JAMA.
[33] R. Westendorp,et al. Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? , 1994, BMJ.
[34] N. Weiss,et al. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women , 1997, The Lancet.
[35] A. Paganini-Hill. Estrogen replacement therapy and stroke. , 1995, Progress in cardiovascular diseases.
[36] H. Genant,et al. Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. , 1987, Annals of internal medicine.
[37] W. Stamm,et al. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. , 1993, The New England journal of medicine.
[38] K. McPherson,et al. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials , 1997, BMJ.
[39] S. Taplin,et al. Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. , 1996, Journal of the National Cancer Institute.
[40] L. Speroff,et al. The heart and estrogen/progestin replacement study (HERS). , 1998, Maturitas.
[41] K. Kerlikowske,et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. , 1995, Obstetrics and gynecology.
[42] N. Wintfeld,et al. Postmenopausal hormone therapy and mortality. , 1997, The New England journal of medicine.
[43] H. Genant,et al. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. , 1997, Archives of internal medicine.